Table 2

Demographics and clinical characteristics

	CD		UC		Total
	n	%	n	%	n	%
Gender
Male	103	53.10	63	54.30	166	53.50
Female	90	46.40	47	40.50	137	44.20
Not available	1	0.50	6	5.20	7	2.30
Total	194	100	116	100	310	100
Ethnicity
Caucasian	189	97.50	108	93	297	95.80
Latin	3	1.50	1	0.90	4	1.30
Gypsy	1	0.50	0	0	1	0.30
Arab	0	0	1	0.90	1	0.30
Not available	1	0.50	6	5.20	7	2.30
Total	194	100	116	100	310	100
Working status
Employed by self	115	59.30	51	44	166	53.50
Self-employed	15	7.70	17	14.50	32	10.30
Retired	16	8.20	16	13.80	32	10.30
Housework	12	6.20	11	9.50	23	7.50
Unemployed	17	8.80	4	3.40	21	6.80
Student	6	3.10	6	5.20	12	3.90
Permanently unable to work	6	3.10	3	2.60	9	2.90
Temporarily unable to work	4	2.10	1	0.90	5	1.60
Other	1	0.50	1	0.90	2	0.60
Not available	2	1	6	5.20	8	2.60
Total	194	100	116	100	310	100
Level of education
Secondary education	101	52.10	46	39.60	147	48.50
Primary education	45	23.20	30	25.90	75	24.50
University education	42	21.60	32	27.60	74	24.30
Uneducated	4	2.10	2	1.70	6	1.90
Not available	2	1	6	5.20	8	2.70
Total	194	100	116	100	310	100
Smoking habits
Non-smoker	86	44.30	70	60.30	156	50.30
Ex-smoker	52	26.80	37	32	89	28.70
Smoker	55	28.40	7	6	62	20
Not available	1	0.50	2	1.70	3	1
Total	194	100	116	100	310	100
Alcohol abuse
No	189	97.40	114	98.30	303	97.70
Yes	4	2.10	0	0	4	1.30
Not available	1	0.50	2	1.70	3	1
Total	194	100	116	100	310	100

	n	Mean	Median	SD	25th percentile	75th percentile
Age at signed informed consent (years)
CD	194	43.8	43	12.8	34.0	51.3
UC	116	46.8	46	13.3	38.0	57.8
Total	310	44.9	44	13	36.0	53.3
Time from diagnosis of IBD to anti-TNFα treatment initiation (months)
CD	193*	89.5	45.5	97.8	11.6	156
UC	115*	77.6	43.8	82.1	10.8	143.8
Total	308	85.0	45.5	92.3	11.1	150.2
Follow-up time from anti-TNFα treatment initiation (months)
CD	92	59.5	59.8	7.9	53.2	65.8
UC	65	59.5	59.8	7.5	53.4	65.1
Total	157	59.5	59.8	7.7	53.3	65.6

*Not available: 1 patient.
anti-TNFα, antitumour necrosis factor alpha; CD, Crohn’s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.